Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 9/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | RAC1 | P63000 | 2/20 | 0.32 |
| ▸ | RAC2 | P15153 | 1/20 | 0.32 |
| ▸ | RAC3 | P60763 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4431742 | 1.00 | MEN1 (0.42) | MEN1KMT2AELANEKDM4CCREBBP | |
| SCHEMBL4419750 | 1.00 | MEN1 (0.42) | MEN1KMT2AELANEKDM4CCREBBP | |
| SCHEMBL4427790 | 1.00 | MEN1 (0.42) | MEN1KMT2AELANEKDM4CCREBBP | |
| SCHEMBL4418500 | 0.99 | ELANE (0.41) | MEN1KMT2AELANEKDM4CCREBBP | |
| SCHEMBL6395404 | 0.97 | ELANE (0.41) | MEN1KMT2AELANEKDM4CCREBBP | |
| SCHEMBL10494139 | 0.89 | ELANE (0.43) | MEN1KMT2AELANEKDM4CCREBBP | |
| SCHEMBL13886253 | 0.89 | ELANE (0.43) | MEN1KMT2AELANEKDM4CCREBBP | |
| SCHEMBL3519875 | 0.88 | ELANE (0.43) | MEN1KMT2AELANEKDM4CCREBBP | |
| SCHEMBL6396592 | 0.87 | ELANE (0.40) | MEN1KMT2AELANEKDM4CCREBBP | |
| SCHEMBL6396957 | 0.86 | MEN1 (0.49) | MEN1KMT2AELANEKDM4CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2009-08-27 | — | — | US | disclosed |
| US-7514432-B2 | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2009-04-07 | — | — | US | disclosed |
| US-7514432-B2 | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2009-04-07 | — | — | US | disclosed |
| US-7514432-B2 | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2009-04-07 | — | — | US | disclosed |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | EXONHIT THERAPEUTICS SA (FR) | 2006-08-17 | — | — | US | disclosed |
| EP-1597253-B1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2006-08-09 | — | — | EP | disclosed |
| EP-1597253-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | Exonhit Therapeutics S.A. (FR) | 2005-11-23 | — | — | EP | disclosed |
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | EXONHIT THERAPEUTICS SA (FR) | 2005-03-10 | — | — | US | disclosed |
| EP-1480966-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | Exonhit Therapeutics S.A. (FR) | 2004-12-01 | — | — | EP | disclosed |
| EP-1471063-A1 | Compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | Exonhit Therapeutics S.A. (FR) | 2004-10-27 | — | — | EP | disclosed |
| WO-2004076445-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2004-09-10 | — | — | WO | disclosed |
| WO-2004076445-A2 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | EXONHIT THERAPEUTICS SA (FR) | 2004-09-10 | — | — | WO | disclosed |
| WO-2003074508-A1 | COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES | EXONHIT THERAPEUTICS SA (FR) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054629-A1 | Compounds and methods of treating cell proliferative diseases | MKI67, CCNC, PCNA | MEN1 482/4885KMT2A 1194/4885ELANE 1534/4885 |
| US-20090216014-A1 | NOVEL COMPOUNDS AND METHODS OF TREATING CELL PROLIFERATIVE DISEASES, RETINOPATHIES AND ARTHRITIS | RB1, ALDH1A2, CDK4 | MEN1 2988/4885KMT2A 1349/4885ELANE 1354/4885 |
| US-20060183749-A1 | Novel compounds and methods of treating cell proliferative diseases, retinopathies and arthritis | RB1, ALDH1A2, CDK4 | MEN1 2988/4885KMT2A 1349/4885ELANE 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.